Scientists find a much faster way to classify our cells – Engadget

Here's how it works: Cells are first placed into wells, where molecular markers attach themselves to each RNA strand. The process is repeated, and eventually each cell type has a unique combination of tags on its RNA molecules. The team can then break the cells open chemically and read back the sequences of tags. "We came up with this scheme that allows us to look at very large numbers of cells at the same time, without ever isolating a single cell," Dr. Jay Shender told the New York Times.

The team tested it using 150,000 cells from Caenorhabditis elegans (roundworm), a tiny worm that has been model for biological research since the 1960s. They not only identified the 27 known cell types, but were able to break them down into groups with mildly different gene arrangements. That includes 40 different neuron types, including a rare example that only forms one cell in very few worms.

We came up with this scheme that allows us to look at very large numbers of cells at the same time, without ever isolating a single cell.

Those results are exciting, but the system doesn't work all the time. With roundworms, for instance, it failed to identify 78 different types of previously identified neurons. "Of course, there is more to do, but I am pretty optimistic that this can be solved," said Rockefeller University's Cori Bargmann, who wasn't directly involved in the study.

The research also must be adapted to the complexities of the human body. Nevertheless, it's very promising, particularly for the Human Cell Atlas initiative being funded in part by the Chan Zuckerberg Initiative. That aims to map every cell in the human body, providing a baseline to compare healthy cells with diseased ones.

The study could reveal signature for pathology, better record cell-to-cell interactions and help scientists interpret genetic variants. The ultimate goal is to "discover targets for therapeutic intervention and ... drive the development of new technologies and and advanced analysis techniques." Much like with new gene sequencing techniques, it could help push medicine and treatments to a new level.

More here:
Scientists find a much faster way to classify our cells - Engadget

Bio-inspired Materials Give Boost to Regenerative Medicine – Bioscience Technology

What if one day, we could teach our bodies to self-heal like a lizards tail, and make severe injury or disease no more threatening than a paper cut?

Or heal tissues by coaxing cells to multiply, repair or replace damaged regions in loved ones whose lives have been ravaged by stroke, Alzheimers or Parkinsons disease?

Such is the vision, promise and excitement in the burgeoning field of regenerative medicine, now a major ASU initiative to boost 21st-century medical research discoveries.

ASU Biodesign Institute researcher Nick Stephanopoulos is one of several rising stars in regenerative medicine. In 2015, Stephanopoulos, along with Alex Green and Jeremy Mills, were recruited to the Biodesign Institutes Center for Molecular Design and Biomimetics (CMDB), directed by Hao Yan, a world-recognized leader in nanotechnology.

One of the things that that attracted me most to the ASU and the Biodesign CMDB was Haos vision to build a group of researchers that use biological molecules and design principles to make new materials that can mimic, and one day surpass, the most complex functions of biology, Stephanopoulos said.

I have always been fascinated by using biological building blocks like proteins, peptides and DNA to construct self-assembled structures, devices and materials, and the interdisciplinary and highly collaborative team in the CMDB is the ideal place to put this vision into practice.

Yans research center uses DNA and other basic building blocks to build their nanotechnology structures only at a scale 1,000 times smaller than the width of a human hair.

Theyve already used nanotechnology to build containers to specially deliver drugs to tissues, build robots to navigate a maze or nanowires for electronics.

To build a manufacturing industry at that tiny scale, their bricks and mortar use a colorful assortment of molecular Legos. Just combine the ingredients, and these building blocks can self-assemble in a seemingly infinite number of ways only limited by the laws of chemistry and physics and the creative imaginations of these budding nano-architects.

Learning from nature

The goal of the Center for Molecular Design and Biomimetics is to usenatures design rulesas an inspiration in advancing biomedical, energy and electronics innovation throughself-assembling moleculesto create intelligent materials for better component control and for synthesis intohigher-order systems, said Yan, who also holds the Milton Glick Chair in Chemistry and Biochemistry.

Prior to joining ASU, Stephanopoulos trained with experts in biological nanomaterials, obtaining his doctorate with the University of California Berkeleys Matthew Francis, and completed postdoctoral studies with Samuel Stupp at Northwestern University. At Northwestern, he was part of a team that developed a new category of quilt-like, self-assembling peptide and peptide-DNA biomaterials for regenerative medicine, with an emphasis in neural tissue engineering.

Weve learned from nature many of the rules behind materials that can self-assemble. Some of the most elegant complex and adaptable examples of self-assembly are found in biological systems, Stephanopoulos said.

Because they are built from the ground-up using molecules found in nature, these materials are also biocompatible and biodegradable, opening up brand-new vistas for regenerative medicine.

Stephanopoulos tool kit includes using proteins, peptides, lipids and nucleic acids like DNA that have a rich biological lexicon of self-assembly.

DNA possesses great potential for the construction of self-assembled biomaterials due to its highly programmable nature; any two strands of DNA can be coaxed to assemble to make nanoscale constructs and devices with exquisite precision and complexity, Stephanopoulos said.

Proof all in the design

During his time at Northwestern, Stephanopoulos worked on a number of projects and developed proof-of-concept technologies for spinal cord injury, bone regeneration and nanomaterials to guide stem cell differentiation.

Now, more recently, in a new studyin Nature Communications, Stephanopoulos and his colleague Ronit Freeman in the Stupp laboratory successfully demonstrated the ability to dynamically control the environment around stem cells, to guide their behavior in new and powerful ways.

In the new technology, materials are first chemically decorated with different strands of DNA, each with a unique code for a different signal to cells.

To activate signals within the cells, soluble molecules containing complementary DNA strands are coupled to short protein fragments, called peptides, and added to the material to create DNA double helices displaying the signal.

By adding a few drops of the DNA-peptide mixture, the material effectively gives a green light to stem cells to reproduce and generate more cells. In order to dynamically tune the signal presentation, the surface is exposed to a soluble single-stranded DNA molecule designed to grab the signal-containing strand of the duplex and form a new DNA double helix, displacing the old signal from the surface.

This new duplex can then be washed away, turning the signal off. To turn the signal back on, all that is needed is to now introduce a new copy of single-stranded DNA bearing a signal that will reattach to the materials surface.

One of the findings of this work is the possibility of using the synthetic material to signal neural stem cells to proliferate, then at a specific time selected by the scientist, trigger their differentiation into neurons for a while, before returning the stem cells to a proliferative state on demand.

One potential use of the new technology to manipulate cells could help cure a patient with neurodegenerative conditions like Parkinsons disease.

The patients own skin cells could be converted to stem cells using existing techniques. The new technology could help expand the newly converted stem cells back in the lab and then direct their growth into specific dopamine-producing neurons before transplantation back to the patient.

People would love to have cell therapies that utilize stem cells derived from their own bodies to regenerate tissue, Stupp said. In principle, this will eventually be possible, but one needs procedures that are effective at expanding and differentiating cells in order to do so. Our technology does that.

In the future, it might be possible to perform this process entirely within the body. The stem cells would be implanted in the clinic, encapsulated in the type of material described in the new work, and injected into a particular spot. Then the soluble peptide-DNA molecules would be given to the patient to bind to the material and manipulate the proliferation and differentiation of transplanted cells.

Scaling the barriers

One of the future challenges in this area will be to develop materials that can respond better to external stimuli and reconfigure their physical or chemical properties accordingly.

Biological systems are complex, and treating injury or disease will in many cases necessitate a material that can mimic the complex spatiotemporal dynamics of the tissues they are used to treat, Stephanopoulos said.

It is likely that hybrid systems that combine multiple chemical elements will be necessary; some components may provide structure, others biological signaling and yet others a switchable element to imbue dynamic ability to the material.

A second challenge, and opportunity, for regenerative medicine lies in creating nanostructures that can organize material across multiple length scales. Biological systems themselves are hierarchically organized: from molecules to cells to tissues, and up to entire organisms.

Consider that for all of us, life starts simple, with just a single cell. By the time we reach adulthood, every adult human body is its own universe of cells, with recent estimates of 37 trillion or so. The human brain alone has 100 billion cells or about the same number of cells as stars in the Milky Way galaxy.

But over the course of a life, or by disease, whole constellations of cells are lost due to the ravages of time or the genetic blueprints going awry.

Collaborative DNA

To overcome these obstacles, much more research funding and recruitment of additional talent to ASU will be needed to build the necessary regenerative medicine workforce.

Last year, Stephanopoulos research received a boost with funding from the U.S. Air Forces Young Investigator Research Program (YIP).

The Air Force Office of Scientific ResearchYIP award will facilitate Nicks research agenda in this direction, and is a significant recognition of his creativity and track record at the early stage of his careers, Yan said.

Theyll need this and more to meet the ultimate challenge in the development of self-assembled biomaterials and translation to clinical applications.

Buoyed by the funding, during the next research steps, Stephanopoulos wants to further expand horizons with collaborations from other ASU colleagues to take his research teams efforts one step closer to the clinic.

ASU and the Biodesign Institute also offer world-class researchers in engineering, physics and biology for collaborations, not to mention close ties with the Mayo Clinic or a number of Phoenix-area institutes so we can translate our materials to medically relevant applications, Stephanopoulos said.

There is growing recognition that regenerative medicine in the Valley could be a win-win for the area, in delivering new cures to patients and building, person by person, a brand-new medicinal manufacturing industry.

Stephanopoulos recent research was carried out at Stupps Northwesterns Simpson Querrey Institute for BioNanotechnology. The National Institute of Dental and Craniofacial Research of the National Institutes of Health (grant 5R01DE015920) provided funding for biological experiments, and the U.S. Department of Energy, Office of Science, Basic Energy Sciences provided funding for the development of the new materials (grants DE-FG01-00ER45810 and DE-SC0000989 supporting an Energy Frontiers Research Center on Bio-Inspired Energy Science (CBES)).

The paper is titled Instructing cells with programmable peptide DNA hybrids. Samuel I. Stupp is the senior author of the paper, and post-doctoral fellows Ronit Freeman and Nicholas Stephanopoulos are primary authors.

See the original post:
Bio-inspired Materials Give Boost to Regenerative Medicine - Bioscience Technology

ASC Biosciences, Inc. to appear on the "Informed" series hosted by Rob Lowe – Markets Insider

PALM DESERT, Calif., Aug. 21, 2017 /PRNewswire/ --ASC Biosciences, Inc. (formerly Nevis Capital Corporation) ("ASC") (OTC Pink Open Markets: "ASCW") is pleased to announce it will appear on the award-winning program "Informed" hosted by Rob Lowe.

Informed is an award-winning program that highlights new stories and innovated concepts through ground breaking short-form and long-form documentary presentation. The program, which is anchored by a veteran production team with decades of industry experience, is able to effectively communicate the most critical stories to a wide and diverse audience. "Informed" is hosted by the inimitable Rob Lowe.

ASC Biosciences, Inc. ("ASC" or the "Company") is a development stage biotechnology company that has a proprietary adult stem cell platform capable of forming nearly every tissue in the human body. These cells, Multipotent Adult Stem Cells ("MASCs"), will differentiate into cartilage, bone, tendon, muscle, ligament, fat, blood vessels, nerves, skin, etc. in humans. MASCs have apparent unlimited proliferation potential (do not reach replicative senescence) and have been shown to regenerate tissues by differentiating into the cell types at the site. MASCs lack the ability to cause a rejection response, and can thus be used as an allogenic transplant - which means that cells harvested from a single donor can be expanded in culture and the expanded cells can be used to treat hundreds, thousands, or millions of patients. TheMissionof ASC Biosciences is to provide surgeons around the world with our proprietary brand of unlimited allogeneic "Stem Cells in a Bottle" to be used in a wide variety of FDA Approved orthopedic and cosmetic therapies, resulting in permanent tissue regeneration; thus avoiding the repeat treatments commonly required in the current generation of approved stem cell therapies. ASC intends to establish an intellectual property portfolio that will provide proprietary dominion in the repair and regeneration of all human tissues. For more information visit:http://www.ascbio.comor @ASCbio1 on Facebook.

ASC trades on the OTC Pink Open Markets under the symbol: ASCW.

Forward-Looking StatementsCertain statements contained herein constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations, estimates and projections about ASC Biosciences, Inc. industry, management's beliefs and certain assumptions made by management. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict.

Because such statements involve risks and uncertainties, the actual results and performance of the Company may differ materially from the results expressed or implied by such forward-looking statements. Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. Unless otherwise required by law, the Company also disclaims any obligation to update its view of any such risks or uncertainties or to announce publicly the result of any revisions to the forward-looking statements made here. Readers should review carefully reports or documents the Company files periodically with the OTC Markets -https://www.otcmarkets.com.

View original content:http://www.prnewswire.com/news-releases/asc-biosciences-inc-to-appear-on-the-informed-series-hosted-by-rob-lowe-300507183.html

SOURCE ASC Biosciences, Inc.

Read the original:
ASC Biosciences, Inc. to appear on the "Informed" series hosted by Rob Lowe - Markets Insider

Want to live longer? Forever Labs wants to help, using your stem cells – Digital Trends

Get today's popular DigitalTrends articles in your inbox:

Why it matters to you

Forever Labs hopes that by storing your stem cells, you can fight disease and slow aging.

We may have found the Fountain of Youth. Or at the very least, weve found Forever Labs. Its a new Y Combinator startup that seeks to help you live longer and healthier by preserving adult stem cells. Because as it turns out, drinking from a mythical source of water is not, in fact, the key to eternity.

While some of us may be familiar with the concept of freezing our eggs, few until now have considered applying the same concept to our stem cells. But this, Forever Labs believes, is a mistake. This is because stem cells can be transformed into any kind of cell the body needs (which is why so much research already exists surrounding these supremely adaptable cells). However, as Forever Labs points out on its website, The number and therapeutic quality of our stem cells diminishes with age. But if you store them, you may be able to preserve them for future use, thereby combating disease and, just maybe, aging.

How does it work? Using a patented device, Forever Labs collects stem cells from your blood marrow, which the team calls a wellspring for stem cells that replenish your blood, bone, immune system, and other vital tissues. The whole process is said to take around 15 minutes, with most clients reporting a five to 10 second pressure-like sensation. And dont worry no scars will result from the process.

Once your cells have been extracted, the company offers to grow and bank your cells for $2,500, as TechCrunch explains. Youll need to pay an extra $250 every year for storing your cells, or if youd rather, just pay a flat fee of $7,000 for life.

If youre looking to get into the storage game earlier rather than later (Forever Labs will start collecting cells as long as youre 18 or over, and suggests that younger is better), then it seems that this $7,000 option might be a bit better. As the loss and decline of bone marrow stem cells continues throughout ones life, Forever Labs notes, and as this decline accelerates with age, storing at anyage may provide benefits to your future self,

So if youre looking for a way to live forever (or just a bit longer), this may be a good way to hedge your bets.

See the rest here:
Want to live longer? Forever Labs wants to help, using your stem cells - Digital Trends

The Adult Brain Can Regenerate Neurons in an Unexpected Area, Says New Study – ScienceAlert

Scientists have discovered for the first time that adult mouse brains produce new cells in the amygdala, a finding that could eventually lead to better treatments for conditions like anxiety and depression, as well as a better understanding of the brain overall.

The amygdala handles a lot of our emotional responses, especially those relating to fear, and broken connections inside it can lead to anxiety disorders such as post-traumatic stress disorder (PTSD).

If the brain is capable of regenerating neurons in the amygdala, then that's potentially one way of fighting back against these mental health issues, according to the team from the University of Queensland in Australia.

"While it was previously known that new neurons are produced in the adult brain, excitingly this is the first time that new cells have been discovered in the amygdala," says one of the team, Pankaj Sah from the Queensland Brain Institute.

"Our discovery has enormous implications for understanding the amygdala's role in regulating fear and fearful memories."

Before now, neurogenesis the process of producing new neurons had only been spotted in human adults in the hippocampus, the part of the brain that handles long-term memory and also deals with emotional responses, and the striatum.

Adult neurogenesis was first recognised in the 1960s, but was more widely accepted in the 1990s, thanks in part to the discovery of stem cells in adult mice brains cells that can divide and develop into other types of cells.

That discovery was made by another team from the Queensland Brain Institute, and since then, scientists have confirmed the same process happens in humans.

Now it looks like it's happening elsewhere too: based on new studies of mice, the researchers found evidence for the same stem cells in the amygdala, cells that could turn into genuine, fully functioning neurons. Now the task is to find the same results in humans.

Right now it's not clear what those new neurons do, or how the brain uses them, but their location is interesting and worthy of further study.

There's so much we still don't know about the brain, though its secrets are slowly being unlocked. As far as neurogenesis goes, for example, we know that a session on the booze slows down the process, though giving up the drink reverses the process.

Meanwhile, a study published in July found that implanting stem cells into the brain can help to extend the lifespan of mice, and it's possible that a similar approach here could also have a positive effect.

"Finding ways of stimulating the production of new brain cells in the amygdala could give us new avenues for treating disorders of fear processing, which include anxiety, PTSD and depression," says one of the team, Dhanisha Jhaveri.

The research has been published in Molecular Psychiatry.

See the original post here:
The Adult Brain Can Regenerate Neurons in an Unexpected Area, Says New Study - ScienceAlert

The Vital Role of Emerging Gene Transfer Methods in T-cell Cancer Therapy – Bioscience Technology

Alternatively, non-viral transfection of DNA plasmids via advanced electroporation techniques, as well as liposomal formulation, nanoparticles, and cell-penetrating peptides, are increasingly being adopted due to their low immunogenicity and low risk of insertional mutagenesis. In particular, non-viral electroporation methods offer further advantages over viral methods, such as being more cost-effective and allowing the delivery of larger gene inserts. Early results suggest CAR T-cells generated by non-viral electroporation methods are effective in treating certain types of cancer (e.g. Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to tyrosine kinase inhibitors). Therefore, all this indicates that non-viral transfection via electroporation is likely to become one of the preferred methods over viral-mediated transduction for engineering CAR T-cells in the future.

Although non-viral bioprocessing methods have great potential over viral methods in terms of their clinical application in human cancer therapy, they present some limitations that need to be overcome before they can be adopted for routine clinical use. Specifically, it has been difficult to validate non-viral methods in human applications, mainly because of the low efficiency of gene transfer they provide and subsequent insufficient integration into the immune system. Yet, enhanced electroporation techniques combined with DNA transposition methods have started to show great promise in resolving these challenges, thus providing fresh impetus for their application in human cancer therapy.

DNA transposition has emerged as a non-viral gene insertion method to generate CAR T-cells. In DNA transposition, transposons (defined segments of DNA) move from one genomic location to another facilitated by one or more proteins, called the transposase. Transposons have been unveiled as a simple, yet powerful, genetic editing tool for mutagenesis (that is, to remove and/or integrate genetic sequences ex vivo) in vertebrates. Transposon-transposase systems have been shown to successfully transfer CAR transgene cassettes into T-cells to produce CAR T-cells for safe, inexpensive, and effective therapeutic purposes, such as the fish-derived Sleeping Beauty (SB) and insect-derived piggyBac human-adapted transposition systems.

Advanced electroporation technologies have transformed the capability of these transposition systems in the non-viral generation of CAR T-cells. Such systems provide highly effective methods for genetically modifying T-cells, amongst other cell types, and can be ideal for more complex transfection scenarios where multiple or even different substrate types need to be co-delivered (for example, CAR T-cell generation). Systems are available that even enable closed transfection to be performed for up to 1x109 cells, allowing for large-scale generation of CAR T-cells for immunotherapy development. These technologies can improve the efficiency of non-viral gene transfer, and so enhance the safe and effective integration of CAR T-cells into a patients immune system.

Given that non-viral transposition is still at an early stage in its clinical application, enhanced approaches to using it are still being investigated to potentially heighten the availability of safe, low cost, and efficient CAR T-cell cancer therapy in routine clinical use. For example, SB transposition of CAR genes from minimalistic DNA vectors called minicircles (MCs) have been found to produce a higher proportion of non-toxic MC-derived CAR transposons compared to those produced by viral methods.

As well as non-viral transposition systems, other new methods have shown promise in reducing the unwanted off-tissue toxicity that can be produced by genetically modified T-cells. By using transiently expressed mRNAs, CAR expression can be switched on or off to limit on-target, off-tissue toxicity to normal tissue. Yet, this technique cannot provide the long-term expression needed for maximal CAR T-cell function and sustained defense against cancer, so requires further investigation.

More recently, CRISPR/Cas9 has been used to introduce CAR sequences into T-cells. Targeted integration of CAR sequences into the TCR locus has allowed for endogenous control of CAR expression with parallel knockout of the TCR, which may generate a more effective and safer CAR T-cell population. CRISPR/Cas9 has also been used to knockout the inhibitory checkpoint PD-1 receptor in T-cells to potentially improve the efficiency of T-cell based therapeutics. These studies highlight the potential of CRISPR/Cas9 genome editing to advance the efficiency, safety, and effectiveness of immunotherapies.

CAR T-cell immunotherapies are becoming increasingly important in treating cancer, especially as non-viral gene modification technologies become more advanced and our understanding of immunology improves. The next challenge is to address how best to ensure robust and sustained CAR T-cell activity, and obtain the required anti-tumor effects without producing off-target toxicity, to improve patient outcomes.

The future of T-cell cancer therapy is likely to involve precision treatments that target the specific molecular mechanisms underpinning cancer in individual patients or groups of patients. This may also combine CAR T-cell therapy with other treatments (e.g. vaccines, checkpoint blockade drugs) to complement each of their respective limitations. Ultimately, manufacturing processes might be able to consistently produce T-cell therapies to the desired specification through automated engineering, or they might become available from a scalable allogeneic off the shelf universal source.

As cancer incidence worldwide continues to rise at an alarming rate, the race to find an effective treatment has never been so important. Yet, the remarkable progress that cancer immunotherapies have made in recent years has given us fresh hope. Advancing genetic engineering approaches and new technologies are enabling us to reinforce our natural immune defenses against cancer, generating ever stronger CAR T-cell therapies to provide cancer patients with the best care possible.

Follow this link:
The Vital Role of Emerging Gene Transfer Methods in T-cell Cancer Therapy - Bioscience Technology

Scientists discover vitamin C regulates stem cell function, curbs leukemia development – Medical Xpress

August 21, 2017 Dr. Michalis Agathocleous (left) and Dr. Sean Morrison. Credit: UT Southwestern

Not much is known about stem cell metabolism, but a new study from the Children's Medical Center Research Institute at UT Southwestern (CRI) has found that stem cells take up unusually high levels of vitamin C, which then regulates their function and suppresses the development of leukemia.

"We have known for a while that people with lower levels of ascorbate (vitamin C) are at increased cancer risk, but we haven't fully understood why. Our research provides part of the explanation, at least for the blood-forming system," said Dr. Sean Morrison, the Director of CRI.

The metabolism of stem cells has historically been difficult to study because a large number of cells are required for metabolic analysis, while stem cells in each tissue of the body are rare. Techniques developed during the study, which was published in Nature, have allowed researchers to routinely measure metabolite levels in rare cell populations such as stem cells.

The techniques led researchers to discover that every type of blood-forming cell in the bone marrow had distinct metabolic signatures - taking up and using nutrients in their own individual way. One of the main metabolic features of stem cells is that they soak up unusually high levels of ascorbate. To determine if ascorbate is important for stem cell function, researchers used mice that lacked gulonolactone oxidase (Gulo) - a key enzyme that most mammals, including mice but not humans, use to synthesize their own ascorbate.

Loss of the enzyme requires Gulo-deficient mice to obtain ascorbate exclusively through their diet like humans do. This gave CRI scientists strict control over ascorbate intake by the mice and allowed them to mimic ascorbate levels seen in approximately 5 percent of healthy humans. At these levels, researchers expected depletion of ascorbate might lead to loss of stem cell function but were surprised to find the opposite was true - stem cells actually gained function. However, this gain came at the cost of increased instances of leukemia.

"Stem cells use ascorbate to regulate the abundance of certain chemical modifications on DNA, which are part of the epigenome," said Dr. Michalis Agathocleous, lead author of the study, an Assistant Instructor at CRI, and a Royal Commission for the Exhibition of 1851 Research Fellow. "The epigenome is a set of mechanisms inside a cell that regulates which genes turn on and turn off. So when stem cells don't receive enough vitamin C, the epigenome can become damaged in a way that increases stem cell function but also increases the risk of leukemia."

This increased risk is partly tied to how ascorbate affects an enzyme known as Tet2, the study showed. Mutations that inactivate Tet2 are an early step in the formation of leukemia. CRI scientists showed that ascorbate depletion can limit Tet2 function in tissues in a way that increases the risk of leukemia.

These findings have implications for older patients with a common precancerous condition known as clonal hematopoiesis. This condition puts patients at a higher risk of developing leukemia and other diseases, but it is not well understood why certain patients with the condition develop leukemia and others do not. The findings in this study might offer an explanation.

"One of the most common mutations in patients with clonal hematopoiesis is a loss of one copy of Tet2. Our results suggest patients with clonal hematopoiesis and a Tet2 mutation should be particularly careful to get 100 percent of their daily vitamin C requirement," Dr. Morrison said. "Because these patients only have one good copy of Tet2 left, they need to maximize the residual Tet2 tumor-suppressor activity to protect themselves from cancer."

Researchers in the Hamon Laboratory for Stem Cell and Cancer Biology, in which Dr. Morrison is also appointed, intend to use the techniques developed as part of this study to find other metabolic pathways that control stem cell function and cancer development. They also plan to further explore the role of vitamin C in stem cell function and tissue regeneration.

Explore further: Vitamin C may encourage blood cancer stem cells to die

More information: Michalis Agathocleous et al. Ascorbate regulates haematopoietic stem cell function and leukaemogenesis, Nature (2017). DOI: 10.1038/nature23876

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

More:
Scientists discover vitamin C regulates stem cell function, curbs leukemia development - Medical Xpress

Belize Biochemist’s Groundbreaking Stem Cell Research – Channel 7 Daily News

Belize Biochemist's Groundbreaking Stem Cell Research
Channel 7 Daily News
A young Belizean's groundbreaking research has been published in a top US medical Journal. On Monday, Aimee Flores, who is pursuing a Ph.D in Stem Cell Research and Bio-chemistry at UCLA had her paper published in the "Nature Cell Biology", ...

and more »

More:
Belize Biochemist's Groundbreaking Stem Cell Research - Channel 7 Daily News

Gene Editing in Human Embryos Leaps ForwardHere’s the Science – Singularity Hub

Imagine walking down the street with a ticking time bomb in your chest, never knowing when your heart may explode.

Or going through five decades of life, having kids, and always wondering when your mind will finally slip away from you. Or worse yet, knowing that one day the same will inevitably happen to your children and your grandchildren.

If there were a curea way to irreversibly correct the faulty biology in yourself and your offspringwould you do it? And knowing that there might be risks, would you be comfortable making that decision for generations to follow?

Last week, a remarkable study published in Nature brought these and other questions back into public discourse. For the first time, an international team led by US scientists used CRISPR, a genetic editing tool, to correct a mutation that leads to heart failure in viable human embryos.

This isnt the first time scientists have tinkered with human embryos. But it is the first that shows that certain off-target effectspreviously thought immensely challengingcan be dealt with in a relatively straightforward way.

In other words, the new technology just brought us one step closer to correcting genetic deficits in humans. And what can be used to right a disease can also be used to enhance a healthy babyartificially altering their intelligence or physical appearance.

To be clear, this study is a long way off from the complicated changes required to make designer babies. This isnt Brave New World or Gattaca.

This is for [the] sake of saving children from horrible diseases, says lead author Dr. Shoukhrat Mitalipov at the Oregon Health and Science University, who previously worked on Dolly the sheep and three-parent babies.

And with this milestone, says Dr. George Church at Harvard University, were one step closer.

The human body runs on the tens of thousands of genes that form the code of life. Sometimes, just a single faulty gene can have devastating consequences, such as Huntingtons disease or hypertrophic cardiomyopathya condition that often leads to heart failure.

For decades, scientists have tried hacking lifes code to cure these genetic diseases at the DNA level. The process seems straightforward: like programmers decoding a bug, scientists would read through the bodys encyclopedia of genes, identify the faulty member, cut and paste the correct code into the original spotand voil, fixed!

The promise of genetic cures seemed easily within reach when a technology called CRISPR came onto the scene in 2012. CRISPR itself isnt a cure. Rather, its a pair of molecular scissors that scientists can direct to almost any point on the human genome and make a precise cut.

The cut triggers a cell to activate a DNA repair program. Almost all cells do this, but embryos go about it slightly differently. If provided with a normal copy of the gene, embryos will use the blueprint gene to reconstruct the broken piece, essentially overwriting the mistaken code. In theory, this leads to fewer mistakes than a normal cells stitch it up repair program, which doesnt use templates.

In practice, however, embryonic DNAs been hard to hack. Just two years ago, Chinese scientists reported giving up on correcting a genetic abnormality in human embryos due to off-target effects, saying that the CRISPR-based technology was too immature.

And for good reason. The safety and ethical barriers are enormous when editing embryosso-called germline editing. The reason is this: after sperm meets egg, the resulting single cell will develop into a persons entire body. This means that any changes to an embryo will (in theory) be present in every single cell in the grown human, including reproductive cells.

In other words, any changes to the embryo will not only affect the person it will become, but also his or her children, and their children and so on. If any unwanted mutation sneaks in during the procedure, the harm is multi-generational.

Then theres the problem of mosaicism. Oftentimes, an edited embryo can lead to a mosaic of genotypes in the resulting cellssome fixed, some not, and the individual still ends up with the disease.

The new study tackles both problems head-on.

Mitalipovs team decided to focus on hypertrophic cardiomyopathy, an inherited disease due to a gene called MYBPC3. People with the condition have two copies of the gene: one normal, one faulty. This means they have a 50-50 chance of passing the condition to their children.

Because the embryo already contains a normal copy of MYBPC3, explain the authors, it already has a blueprint the cell could use to repair the abnormal one. The team recruited a dozen healthy egg donors and one sperm donor that carried the faulty MYBPC3.

Normally, scientists encode all CRISPR components into an external bit of DNA called a plasmid, put that into a cell and rely on the cell to make the necessary proteins and molecules. Mitalipovs team took a more unusual route: using a tiny syringe, they directly injected the CRISPR machinery into either a fertilized embryo or into the egg cell right before fertilization.

In the first case, the CRISPR machinery sticks around for a long time. This increases the chance that it might go rogue and snip parts of the DNA it wasnt designed to cut.

By directly injecting the components, the CRISPR scissors are chewed up by the recipient cell after they do their work: less random snipping, more precision.

The tactic worked. When the team analyzed the resulting embryos at the four- or eight-cell stage, they found 72 percent contained only normal copies of the MYBPC3 gene, compared to roughly 50 percent found in non-edited controls.

Even though the yield of wild type/wild type embryos is still higher, its not 100 percent. We have room to improve, says Mitalipov.

Heres the kicker: using a variety of modern genetic sequencing techniques, the team scrutinized the embryos genomes for off-target effects. They couldnt find any. For all intents and purposes, the edited embryos looked completely healthy.

This doesnt necessarily mean the team avoided all unexpected mutations. It just means any genetic deletions or inserts didnt affect the embryos normal development.

Thats not all. The team also surprisingly found a way to minimize mosaicism. The key is to inject CRISPR components into the egg at the same time as they pumped in the sperm to fertilize it. This is much earlier in the developmental stage than anyone had previously attempted.

It worked. Out of the 58 treated eggs fertilized with the mutant sperm, 42 contained two normal copies of MYBPC3. Only one became a mosaic. In contrast, CRISPRing a fertilized embryo led to 13 out of 54 mosaics.

It makes previous work look pretty amateurish in terms of mosaicism and in terms of off-target effects, says Church.

Surprisingly, rather than bolstering a designer baby future, the study may have inadvertently doused a cold case of biological reality on the sci-fi idea.

Dr. Robin Lovell-Badge, a developmental biologist at the Francis Crick Institute in London, pointed out that the most unexpected result of the study is how the embryo chose to repair the gene.

In one experiment, the team tried introducing an artificial template of MYBPC3 in addition to the normal copy already present in the cell (from the healthy moms). But the cells completely ignored the researchers template, instead exclusively opting to use the maternal MYBPC3 to repair the mutation.

This suggests that you couldnt add anything that wasnt already there, says Lovell-Badge.

To Mitalipov, the crux of the conversation should be solidly based in therapy. My goal has always been to treat genetic diseases that have no cures, to save children, he says.

And there are still a lot of kinks that need ironing out before CRISPR could enter clinics. For one, scientists still hope to increase precision and accuracy. For another, IVF clinics already have solid screening protocols in place to weed out genetic abnormalities before implantation. While CRISPR can, in theory, boost the number of healthy embryos, it would have to work better to justify the cost.

To Dr. Richard Hynes, a cancer researcher at MIT who co-led a national committee that recently published a new guideline for editing embryos, the study is a big breakthrough.

What our report said was, once the technical hurdles are cleared, then there will be societal issues that have to be considered and discussions that are going to have to happen. Nows the time, he says.

Image Credit: University of Michigan via Flickr

Read this article:
Gene Editing in Human Embryos Leaps ForwardHere's the Science - Singularity Hub

Global Cancer Biological Therapy Market 2017 Size, Development Status, Type and Application, Segmentation … – Digital Journal

""Cancer Biological Therapy Market""

WiseGuyReports.com adds Cancer Biological Therapy Market 2017 Global Analysis, Growth, Trends and Opportunities Research Report Forecasting to 2023reports to its database.

Cancer Biological Therapy Market:

Executive Summary

Biological therapy treatment is done with the help of living organisms, parts of living organisms or laboratory manufactured version of such content. There are various types of biological therapies, which inhibit specific molecules involved in development and growth of cancer tumor. Such therapies known as; cancer targeted therapies.

The global cancer biological therapy market is expected to reach USD 82,276.8 million by 2023 at a CAGR of 4.7% during the forecasted period.

The global cancer biological therapy market is segmented on the basis of phases, types, end users and regions. On the basis of phases, the market is segmented into phase I, phase II and phase III. In stage I & II the real impact of these therapies is seen and giving a success rate of 35% in Phase 1 and 20% in Phase II. The success rate of phase I is 35%.

On the basis on types, the global cancer biological therapy market is segmented into monoclonal antibodies, cancer growth blockers, interferons, interleukins, gene therapy, targeted drug delivery, colony stimulating factor, cancer vaccines and others. Monoclonal antibodies accounted for the largest market share of the global cancer biological therapy market. Colony stimulating factor is the fastest growing market at a CAGR of 5.2% during the forecasted period.

On the basis on end users, hospitals & clinics dominates the global cancer biological therapy market. Registering USD 26,790.6 million in 2016 and expected to reach at USD 38,471.9 million by 2023 at the rate of 4.4 % from 2016-2023.

On the basis of regions, the market is segmented into North America, Europe, Asia-Pacific and the Middle East & Africa. North America has the dominating market for cancer biological therapy. The cancer biological therapy market for North America is estimated at USD 19,481.2 million in 2016 and expected to reach by USD 29,516.9 million by 2023 at a fastest CAGR of 5.10%.

Request Sample Report @ https://www.wiseguyreports.com/sample-request/1793685-global-cancer-biological-therapy-analysis-forecast-2016-to-2023

Key Players

The leading market players in the global cancer biological therapy market include Merck Inc., F. Hoffmann-La Roche Ltd, Novartis AG, Amgen Inc., Bristol-Myers Squibb, Celgene, ELI Lilly and Company, EnGeneIC, and Pfizer

Study objectives

Target Audience

For further information on this report, visit -https://www.wiseguyreports.com/enquiry/1793685-global-cancer-biological-therapy-analysis-forecast-2016-to-2023

Key Findings

The reports also covers regional analysis

o US

o Canada

o Germany

o France

o U.K.

o Italy

o Spain

o Rest of Europe

o Japan

o China

o India

o Republic of Korea

o Rest of Asia-Pacific

o Middle East

o Africa

Continued

Buy this Report@https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=1793685

Media Contact Company Name: Wiseguyreports.com Contact Person: Norah Trent Email: sales@wiseguyreports.com Phone: +1 646 845 9349, +44 208 133 9349 City: Pune State: Maharashtra Country: India Website: http://www.wiseguyreports.com

Here is the original post:
Global Cancer Biological Therapy Market 2017 Size, Development Status, Type and Application, Segmentation ... - Digital Journal